Botulinum toxin and Gross Motor Function Classification System: a 17-year Retrospective Study on Target Muscles and Doses
Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação · 09.09.2025
DOI: 10.25759/spmfr.566 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação, erschienen am 09.09.2025. Verfasst von João Luís und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Botulinum toxin type A (BoNT-A) is widely used to manage focal spasticity in children with cerebral palsy (CP), the leading cause of spasticity in childhood. Injections aim to improve function, gait, positioning, hygiene, appearance, and pain control.
Objectives
This single-center retrospective study analyzed the use of anobotulinumtoxinA and abobotulinumtoxinA in children with CP, using each injection session as the unit of analysis. We examined the relationship between Gross Motor Function Classification System (GMFCS) levels and the muscles targeted, and secondarily described demographics, doses, and adverse reactions.
Methods
All injection sessions performed between 2007 and 2023 in patients under 19 years old were reviewed. Ambulatory children were defined as those walking independently or with walking aids (GMFCS ≤ III), while nonambulatory children required a wheelchair for mobility (GMFCS > III). Duplicate records were removed prior to analysis. Between-group comparisons were performed using the Mann-Whitney U test(IBM SPSS v.28). Statistical significance was set at p< 0.05 with effects reported using 95% confidence intervals.
Results
A total of 883 BoNT-A injection sessions were analyzed in 163 children (median age 8.2 IQR 5.1-12.3). OnabotulinumtoxinA (627 sessions) and abobotulinumtoxinA (256 sessions) were administered at mean doses of 187 IU (95% CI 179-194) and 564 IU (95% CI 544-586). Doses were significantly higher in non-ambulatory children for both total and weight-adjusted values (p< 0.001). The most frequently injected muscles in non-ambulatory children were the adductors and hamstrings, while ambulatory children more often received injections in the gastrocnemius, soleus, and tibialis posterior. No severe adverse events were reported.
Conclusions
BoNT-A is a safe and effective treatment for pediatric spasticity across all GMFCS levels. Adapting muscle selection and dosing according to functional level optimizes therapeutic outcomes and helps prevent deformities. Clinically, this supports individualized toxin protocols integrated into long-term rehabilitation programs. The main limitation is the retrospective, single-center design, which may restrict generalizability.
Schlagwörter
Zitieren
APA
Luís, J., Cordeiro, D., Pereira, G. M. E., Pinheiro, F., Lorga, S., Freitas, M., & Almeida, S. (2025). Botulinum toxin and Gross Motor Function Classification System: a 17-year Retrospective Study on Target Muscles and Doses. Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação. https://doi.org/10.25759/spmfr.566
Vancouver
Luís J, Cordeiro D, Pereira GME, Pinheiro F, Lorga S, Freitas M, et al. Botulinum toxin and Gross Motor Function Classification System: a 17-year Retrospective Study on Target Muscles and Doses. Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação. 2025. doi:10.25759/spmfr.566
BibTeX
@article{Lus2025,
author = {Luís, João and Cordeiro, David and Pereira, Gonçalo Martins e and Pinheiro, Fernanda and Lorga, Sara and Freitas, Margarida and Almeida, Susana},
title = {Botulinum toxin and Gross Motor Function Classification System: a 17-year Retrospective Study on Target Muscles and Doses},
journal = {Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação},
year = {2025},
doi = {10.25759/spmfr.566}
}
EUVIMED